No profile data available.
Genmab A/S (GMAB) is a healthcare company in the blood cancer treatment drugs industry, based in Copenhagen, Denmark, with about 3,119 full-time employees.
It reported revenue of $3.72 billion for fiscal year 2025, up 23.9% from fiscal year 2024, and net income of $963.00 million. In Q2 2026 (the quarter ended June 30, 2026) revenue was $1.16 billion, up 24.9% from a year before. Denmark was its largest region in fiscal year 2025, with 89% of revenue. Its market capitalization was $22.79 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.
Genmab A/S reported $3.72 billion in revenue for fiscal year 2025, up 23.9% from $3.00 billion in fiscal year 2024. In Q2 2026 revenue was $1.16 billion.
Denmark: 89% of revenue by region in fiscal year 2025, followed by Japan (6%).
$22.79 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (blood cancer treatment drugs) include BeOne Medicines AG (ONC), Legend Biotech Corporation (LEGN), Sellas Life Sciences Group, Inc. (SLS), Ascentage Pharma Group International (AAPG).